Lewy Body Dementia

Lewy bodies, the protein clumps that define Lewy body dementia and related diseases, contain alpha-synuclein tangled together with many other cell components, but how they form is unclear. This laboratory study examined how disease-linked variants of alpha-synuclein behave differently from the normal protein, appearing to make "sticky," non-functional connections that pull in other molecules and seed the clumps. Understanding the earliest steps of Lewy body formation could reveal ways to interrupt the process that underlies these disorders.

Changes in the GBA1 gene are among the most important inherited risk factors for both Parkinson's disease and dementia with Lewy bodies. GBA1 provides instructions for a lysosomal enzyme that helps cells break down certain fats; when it doesn't work well, waste builds up and protein disposal falters, promoting the alpha-synuclein clumps seen in these diseases. This review explains that biology in accessible terms and why GBA1 has become a leading target for treatments aiming to slow Lewy body diseases in genetically at-risk people.

Brain cells dispose of worn-out mitochondria (their power plants) through a clean-up process called mitophagy. Studying human autopsy brains, researchers found this process is altered in Lewy body dementia and is influenced by both coexisting pathologies and inherited factors, including the APOE4 gene and a variant near the ZMIZ1 gene identified through genetic screening. Linking specific genes to a concrete cellular defect helps explain why the disease varies from person to person and suggests mitophagy as a possible target for future therapies.

The APOE ε4 gene variant raises the risk of several dementias, including dementia with Lewy bodies. This study of 171 people with DLB looked at whether combining a person's APOE genotype with ordinary blood-fat (lipid) measurements could serve as a useful marker for the disease. Testing simple, inheritable-risk-informed blood measures is attractive because it could make diagnosis and risk assessment easier and less invasive, though findings like these need confirmation before they change everyday practice.

Lewy body disease involves buildup of the protein alpha-synuclein, and inflammation is thought to contribute. Because immune-system genes called HLA have been tied to Parkinson's disease, researchers examined whether HLA variants relate to the amount of brain pathology in 539 people with confirmed Lewy body disease. Using whole-genome sequencing, they found one significant and several suggestive links between particular HLA versions and pathology measures, including associations with amyloid levels and with a more widespread disease subtype. The results point to immune-related genetic factors playing a part in how the disease develops.

Lewy body dementia is the second most common dementia, yet most of its inherited risk is still unmapped. In the largest genetic study of its kind, over 4,200 patients compared with 189,000 others, researchers confirmed four known risk regions (APOE, GBA, BIN1, and SNCA) and uncovered a new one, SYT16. They also linked dozens of risk genes to biological pathways and possible drug targets. Large studies like this build the foundational map of what makes the disease heritable and where future treatments might aim.

This large study searched the whole genome for genetic influences on the brain changes seen in Lewy body disease, analyzing nearly 1,500 confirmed cases across discovery and replication groups. It tested 11 measures of pathology, including tangle stage, amyloid level, Lewy body counts, and disease subtype. The APOE e4 variant was strongly linked to greater tangle and amyloid burden and to a more diffuse disease subtype, even in cases with little Alzheimer's-type pathology. Mapping the genetics behind these features helps explain why the disease looks different from person to person.

A faulty GBA1 gene, which makes the enzyme glucocerebrosidase (GCase), is one of the most important genetic risk factors for Lewy body disease and Parkinson's. But some people have low GCase activity without a GBA1 mutation, suggesting other genes act as modifiers. This genome-wide study searched for common gene variants that influence GCase activity. Understanding what tunes this enzyme up or down could reveal new risk factors and point toward treatments that boost GCase, an actively pursued strategy in Lewy body disease.

Lewy body dementia (LBD) is hard to study because it usually blends the pathologies of Parkinson's and Alzheimer's, with alpha-synuclein clumps, tau tangles, and amyloid plaques often occurring together. This review examines the laboratory animal and cell models currently used, which were mostly built for Parkinson's or Alzheimer's, and assesses how well each reproduces LBD's distinctive mix. The authors point out where these models fall short and propose ways to build better ones, an important step toward testing treatments aimed specifically at Lewy body dementia rather than its neighboring diseases.

When mitochondria are damaged, cells tag them for recycling, a process called mitophagy. This US study measured a specific marker of that damage in more than 1,000 autopsy-confirmed Lewy body disease brains and ran a genome-wide search for genes affecting it. The APOE ε4 variant, already a major dementia risk gene, was linked to more mitochondrial damage and heavier disease burden, confirmed in mouse and stem-cell models. A second variant near ZMIZ1 appeared protective. The work ties inherited genetics to failing mitochondrial cleanup and flags genes that may drive risk or resilience.

Parkinson's disease and Lewy body dementia look and behave alike, but their shared genetic roots have been unclear. This Chinese study combined brain-protein data with large genetic studies of both conditions to find culprits they have in common. It identified proteins and genetic regions shared by the two diseases, notably the gene TMEM175, which was reduced in patients' brains, along with DOC2A. Pinpointing genes that underlie both Parkinson's and Lewy body dementia helps explain why they overlap and offers targets that might eventually be treated across both conditions.

Faltering mitochondria, the cell's power plants, are suspected in many brain diseases. This Chinese study used Mendelian randomization, which harnesses genetic variants to infer cause and effect, to test whether 66 mitochondrial proteins influence dementia with Lewy bodies (DLB). A genetically predicted rise in two proteins was linked to higher DLB risk, while three others appeared protective. Because these inferences come from inherited genetic differences, they strengthen the case that mitochondrial biology helps drive DLB and highlight specific proteins that could become targets for future therapies.

Dementia with Lewy bodies (DLB) and Parkinson's disease share genetic risk factors, notably mutations in GBA1 and the APOE ε4 variant. This European study followed 121 DLB and 117 Parkinson's patients, measuring the activity of the GBA-linked enzyme glucocerebrosidase and levels of amyloid-beta 42 in spinal fluid, then tracked thinking over time. Lower amyloid-beta 42 predicted faster cognitive decline in DLB, while reduced enzyme activity predicted faster decline in Parkinson's, independent of the underlying gene mutations. Such biomarkers could help forecast who will decline more quickly and personalize care.

Most genetic studies of dementia with Lewy bodies (DLB) have focused on people of European descent, leaving Asian populations understudied. This Japanese genome-wide study compared 211 DLB patients with over 6,000 controls and found a new risk region (DHTKD1) specific to East Asians, plus a second suggestive one, while confirming the well-known APOE risk gene. Combining data across ethnicities also confirmed the SNCA (alpha-synuclein) gene. Studying diverse populations like this fills in the global genetic map of DLB and can improve diagnosis and risk prediction for everyone.

Problems with fat (lipid) metabolism have been tied to several brain diseases, and this Chinese study asked whether specific lipids causally affect dementia with Lewy bodies (DLB). Using Mendelian randomization, a method that uses genetic variants to test cause and effect, the researchers examined 179 lipid types against genetic data from nearly 3,000 DLB cases. A genetic tendency toward one lipid raised DLB risk, while higher levels of several others appeared protective. The findings point to lipid pathways as possible contributors to DLB and as leads for future prevention or treatment.

Beyond the DNA sequence itself, chemical epigenetic tags and the mix of small molecules (metabolites) in the brain can reveal disease. This US study analyzed postmortem brain tissue from people with dementia with Lewy bodies (DLB) and controls, mapping both DNA methylation and metabolites. It found thousands of methylation differences, mostly added tags near gene start sites, and 15 altered metabolites, with fat-molecule (phosphatidylethanolamine) production most affected. Notably, patterns differed between men and women. These molecular signatures could become diagnostic markers and shed light on the biology behind DLB.

The SHIMMER study tested CT1812, an oral drug that blocks the sigma-2 receptor and is intended to stop toxic protein clumps from damaging synapses, in 130 people with mild to moderate dementia with Lewy bodies at 34 United States sites. Participants took one of two doses or placebo for six months. Alongside safety, the study collected cognitive, motor and behavioral measures and a large panel of biomarkers.

What happenedThe trial completed in late 2024 and posted results in 2026. Its primary purpose was safety and tolerability, and the drug was generally tolerated, with adverse events broadly comparable across the treatment and placebo groups. The efficacy measures in a study this size were exploratory rather than definitive, and the sponsor has used them to size and design the next stage of the program rather than to claim a clinical benefit.

A Georgetown University study of vodobatinib (K0706), a tyrosine kinase inhibitor of the same family as the cancer drug nilotinib, in dementia with Lewy bodies. The idea was that these drugs might help the brain clear abnormal alpha-synuclein. Twenty-nine participants took one of two doses or placebo for twelve weeks, followed by a washout period, with safety, spinal-fluid and blood biomarkers, and cognitive, behavioral and motor testing.

What happenedThe study was terminated before completing enrollment. The reason given was not a problem in this trial but in a much larger one: an interim analysis of PROSEEK, a 442-patient Parkinson's disease study of the same drug, showed no evidence of treatment benefit, so continuing was not justified. Results from the participants who did take part were posted in 2026, and the safety data showed no signal of concern.

PRESENCE tested mevidalen (LY3154207), a drug designed to boost dopamine D1 receptor signalling, in 344 people with Lewy body dementia, covering both dementia with Lewy bodies and Parkinson's disease dementia. Participants at 77 sites took one of three doses or placebo for twelve weeks, with attention, the symptom that fluctuates so noticeably in this disease, as the main measure. It was one of the largest treatment trials ever run specifically in Lewy body dementia.

What happenedThe trial completed in 2020 and did not meet its primary endpoint: none of the three doses improved the continuity-of-attention score more than placebo. Some secondary measures of motor function and daily activities looked better on the higher doses, which is why the compound was later carried into Parkinson's disease studies rather than abandoned outright. For Lewy body dementia specifically, mevidalen was not taken forward.

AscenD-LB tested neflamapimod, a tablet that blocks p38 alpha kinase, an enzyme involved in inflammation and in the health of the basal forebrain cholinergic system, one of the earliest circuits damaged in dementia with Lewy bodies. Ninety-one people at 24 sites in the United States and the Netherlands took neflamapimod or placebo for sixteen weeks, with a battery of attention and memory tests as the main outcome.

What happenedThe study completed in 2020 and the posted analysis showed a small advantage for neflamapimod over placebo on the pre-specified cognitive battery, reported at p=0.049, which counts as a borderline positive result in a trial of this size. Encouraging rather than conclusive, it was enough to justify a larger follow-on program, and neflamapimod has continued into further dementia with Lewy bodies studies since.

This was a relapse-prevention trial of pimavanserin, a drug that acts on serotonin rather than dopamine receptors, in people with hallucinations and delusions caused by dementia, including dementia with Lewy bodies. Everyone first took the drug openly for twelve weeks; those who responded were then randomized either to stay on it or to switch to placebo, and the study measured how long it took for the psychosis to come back.

What happenedThe trial was stopped early in 2019 for efficacy: relapse was significantly less likely on pimavanserin than on placebo (hazard ratio 0.35, p=0.0023), so continuing to randomize people to placebo was no longer justified. The FDA nonetheless declined to extend pimavanserin's approval to dementia-related psychosis in 2021, citing the mix of dementia types studied. The drug remains approved for Parkinson's disease psychosis, and this trial is still the strongest evidence behind its off-label use in Lewy body dementia.

HEADWAY-DLB tested intepirdine (RVT-101), a drug intended to increase acetylcholine signalling on top of standard treatment, in 484 people with dementia with Lewy bodies across seven countries. Participants took one of two doses or placebo for 24 weeks. The main measure was the motor section of the Unified Parkinson's Disease Rating Scale, chosen because movement problems are among the most disabling features of the condition.

What happenedThe trial completed in late 2017 and missed its primary endpoint: neither dose separated from placebo on the motor scale. Intepirdine had already failed a large Alzheimer's disease trial weeks earlier, and its development was stopped altogether. The result is part of the reason that treatment research in dementia with Lewy bodies has since moved away from boosting acetylcholine and toward the underlying alpha-synuclein and inflammatory biology.